Literature DB >> 26807896

The Short Breath-Hold Technique, Controlled Aliasing in Parallel Imaging Results in Higher Acceleration, Can Be the First Step to Overcoming a Degraded Hepatic Arterial Phase in Liver Magnetic Resonance Imaging: A Prospective Randomized Control Study.

Jung Lim Yoo1, Chang Hee Lee, Yang Shin Park, Jeong Woo Kim, Jongmee Lee, Kyeong Ah Kim, Hae Young Seol, Cheol Min Park.   

Abstract

OBJECTIVE: The aim of this study was to assess whether a short breath-hold technique can improve hepatic arterial phase (HAP) image quality in gadoxetic acid-enhanced magnetic resonance (MR) imaging compared with a conventional long breath-hold technique.
MATERIALS AND METHODS: Institutional review board approval and patient consent were obtained for this prospective randomized control study. One hundred nineteen patients undergoing gadoxetic acid-enhanced MR imaging were randomly assigned to groups A or B. Group A patients underwent an 18-second long breath-hold MR technique (conventional VIBE [volumetric interpolated breath-hold examination] technique with GRAPPA [generalized autocalibrating partially parallel acquisition]), and group B patients underwent a 13-second short breath-hold MR technique (VIBE technique with CAIPIRINHA [controlled aliasing in parallel imaging results in higher acceleration]). Respiratory-related graphs of the precontrast and HAP were acquired. The breath-hold degree was graded based on the standard deviation (SD) value of respiratory waveforms. Gadoxetic acid-related dyspnea was defined as when the SD value of the HAP was 200 greater than that of the precontrast phase without degraded image quality in the portal and transitional phases (SD value of the HAP - SD value of the precontrast phase). The overall image quality and motion artifacts of the precontrast and HAP images were evaluated. The groups were compared using the Student t or Fisher exact test, as appropriate.
RESULTS: The incidence of breath-holding difficulty (breath-hold grades 3 and 4) during the HAP was 43.6% (27/62) and 36.8% (21/57) for group A and B, respectively. The SD value during the precontrast phase and the SD value difference between the precontrast and HAP were both significantly higher in group A than in group B (P = 0.047 and P = 0.023, respectively). Gadoxetic acid-related dyspnea was seen in 19.4% (12/62) of group A and 7.0% (4/57) of group B. Group B showed better precontrast and HAP image quality than group A (P < 0.001). Degraded HAP (overall image quality ≥4) was observed in 9.7% (6/62) and 3.5% (2/57) of group A and B, respectively.
CONCLUSIONS: The short breath-hold MR technique, CAIPIRINHA, showed better HAP image quality with less degraded HAP and a lower incidence of breath-hold difficulty and gadoxetic acid-related dyspnea than the conventional long breath-hold technique.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26807896     DOI: 10.1097/RLI.0000000000000249

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  9 in total

1.  Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging.

Authors:  Yang Shin Park; Jongmee Lee; Jeong Woo Kim; Cheol Min Park; Chang Hee Lee
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

2.  Abbreviated Gadoxetic Acid-enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation.

Authors:  Jeong Woo Kim; Chang Hee Lee; Yang Shin Park; Jongmee Lee; Kyeong Ah Kim
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

3.  Evaluation of Transient Motion During Gadoxetic Acid-Enhanced Multiphasic Liver Magnetic Resonance Imaging Using Free-Breathing Golden-Angle Radial Sparse Parallel Magnetic Resonance Imaging.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Kai Tobias Block; Hersh Chandarana; Berthold Kiefer; Yohan Son
Journal:  Invest Radiol       Date:  2018-01       Impact factor: 6.016

4.  Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study.

Authors:  Luigi Grazioli; Riccardo Faletti; Barbara Frittoli; Giacomo Battisti; Roberta Ambrosini; Laura Romanini; Marco Gatti; Paolo Fonio
Journal:  Radiol Med       Date:  2018-08-06       Impact factor: 3.469

5.  Transient severe motion during arterial phase in patients with Gadoxetic acid administration: Can a five hepatic arterial subphases technique mitigate the artifact?

Authors:  Yu-Dong Xiao; Cong Ma; Jun Liu; Hua-Bing Li; Shun-Ke Zhou; Zi-Shu Zhang
Journal:  Exp Ther Med       Date:  2018-01-17       Impact factor: 2.447

6.  CAIPIRINHA-Dixon-TWIST (CDT)-VIBE MR imaging of the liver at 3.0T with gadoxetate disodium: a solution for transient arterial-phase respiratory motion-related artifacts?

Authors:  Leonhard Gruber; Vera Rainer; Michaela Plaikner; Christian Kremser; Werner Jaschke; Benjamin Henninger
Journal:  Eur Radiol       Date:  2017-12-20       Impact factor: 5.315

7.  Evaluation of transient respiratory motion artifact at gadoxetate disodium-enhanced MRI-Influence of different contrast agent application protocols.

Authors:  Kristina I Ringe; Christian von Falck; Hans-Jürgen Raatschen; Frank Wacker; Jan Hinrichs
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

8.  Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi-institutional analysis.

Authors:  Christian Wybranski; Florian Siedek; Robert Damm; Angelos Gazis; Ortrud Wenzel; Stefan Haneder; Thorsten Persigehl; Susanne Steinhauser; Maciej Pech; Frank Fischbach; Katharina Fischbach
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

9.  Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases.

Authors:  Vincenza Granata; Roberta Fusco; Francesca Maio; Antonio Avallone; Guglielmo Nasti; Raffaele Palaia; Vittorio Albino; Roberto Grassi; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2019-11-27       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.